Fig. 2: Time on study, in terms of treatment cycles for each patient (n = 35). | BJC Reports

Fig. 2: Time on study, in terms of treatment cycles for each patient (n = 35).

From: A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors

Fig. 2

Dose level cohorts are shown as DL1(green), DL2(yellow), DL3(orange, and DL4+Expansion(blue)). Cycle at which disease progression was determined either clinically or radiographically is marked by a red triangle. Patients who had previously been exposed to gemcitabine treatment and progressed prior to participation in this study are marked by a black square.

Back to article page